Welcome to this week's Chutes and Ladders, our roundup of hirings and firings throughout the industry. Please send the good word--or the bad--from your shop to Michael Gibney (email | Twitter) or Emily Mullin (email | Twitter) and we will feature it here at the end of each week.
Bristol's senior VP of global development retires
Bristol-Myers Squibb's ($BMY) Brian Daniels, senior vice president of global development and medical affairs, will leave the company in July this year, having served almost 15 years with the company. Daniels led the development of the revolutionary melanoma drug Yervoy, according to the company, as well as the next-generation clot-buster Eliquis. Release
|
Biotech
> Elekta has appointed Åsa Hedin as executive vice president of corporate strategy and Maurits Wolleswinkel as executive vice president of neuroscience. Release
> Neuralstem ($CUR) has appointed Sandford Drexel Smith, the former executive vice president of Genzyme, to its board of directors. Release
> John Harland has joined Vaxart as chief financial officer, replacing David Madden, who served as acting CFO. Release
> Scil Proteins has appointed Dr. Henning Afflerbach as CEO and Dr. Ulrich Haupts as managing director in addition to his current role as chief scientific officer. Release
> Tokai Pharmaceutical has appointed Khalid Mamlouk as vice president and head of medical affairs. Release
> Global Genomics Group has appointed Harry "Chip" Davis Jr. as chief drug development officer. Release
> GW Pharmaceuticals ($GWPH) has appointed Dr. Kenneth Sommerville to the newly created position of vice president of clinical science. Release
> Dr. Paul Billings joined Omicia as its chief medical officer. Release
> Memorial Sloan-Kettering's Dr. Howard Scher will continue to lead its Phase I trial for AV Therapeutics' prostate cancer drug. Release
> ProGDerm brought on J. Michael Delmage as its CEO. Release
> Eleven Biotherapeutics ($EBIO) appointed Dr. Gary Sternberg as its executive vice president of corporate and business development. Release
> Dr. Gaurav Aggarwal joined Ocera Therapeutics as the company's chief business officer. Release
Pharma
> Pharmagen has added Frederick Mundt as senior vice president of sales. Release
> Former Forest Laboratories ($FRX) general counsel Herschel Weinstein joined Lowenstein Sandler as senior counsel and vice chair. Release
> Rich Pharmaceuticals appointed Chieanchuang Kalayanamitr to its medical advisory board. Release
Diagnostics
> DNA Electronics appointed Dr. Steve Allen as chief operating officer. Release
Drug Delivery
> Unilife ($UNIS) appointed John Ryan as senior vice president, general counsel and secretary. Release
CRO
> Cobra Biologics has appointed Daniel Smith as its chief scientific officer. Release
Vaccines
> Novavax ($NVAX) appointed Sven Andreasson as the company's senior vice president of corporate development. Release